Onyvax's products are being developed for the treatment of prostate
cancer, one of the most common cancers today. Onyvax believes its
therapies will be able to prolong life for cancer patients while
helping to maintain a high quality of life.
Onyvax-P is a Cell Vaccine being
developed for prostate cancer treatment. The current study follows
the successful completion of a Phase IIa trial in which almost half
of the patients showed significant decreases in their PSA velocity.
In addition, the time to disease progression was lengthened relative
to that normally expected in a population at this stage of the disease
(Clinical Cancer Res (2005) 11:4469-4478).
Onyvax-P consists of a combination of inactivated cell lines that
are representative of different stages of the disease.